Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 2
2010 4
2011 2
2012 3
2014 2
2015 5
2016 3
2017 2
2018 1
2019 3
2020 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. Among authors: murphy cg. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Reply to Z.R. McCaw et al.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. Among authors: murphy cg. J Clin Oncol. 2023 Oct 10;41(29):4705-4706. doi: 10.1200/JCO.23.00752. Epub 2023 Aug 3. J Clin Oncol. 2023. PMID: 37535884 No abstract available.
The Role of CDK4/6 Inhibitors in Breast Cancer.
Murphy CG. Murphy CG. Curr Treat Options Oncol. 2019 May 18;20(6):52. doi: 10.1007/s11864-019-0651-4. Curr Treat Options Oncol. 2019. PMID: 31101994 Review.
CDK4/6 inhibitors in breast cancer.
Dukelow T, Kishan D, Khasraw M, Murphy CG. Dukelow T, et al. Among authors: murphy cg. Anticancer Drugs. 2015 Sep;26(8):797-806. doi: 10.1097/CAD.0000000000000249. Anticancer Drugs. 2015. PMID: 26053278 Review.
HER2-positive breast cancer: beyond trastuzumab.
Murphy CG, Fornier M. Murphy CG, et al. Oncology (Williston Park). 2010 Apr 30;24(5):410-5. Oncology (Williston Park). 2010. PMID: 20480738 Free article. Review.
The Role of CDK4/6 Inhibition in Breast Cancer.
Murphy CG, Dickler MN. Murphy CG, et al. Oncologist. 2015 May;20(5):483-90. doi: 10.1634/theoncologist.2014-0443. Epub 2015 Apr 15. Oncologist. 2015. PMID: 25876993 Free PMC article. Review.
31 results